Sanritatug vs SCTC21C

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Systemic Lupus Erythematosus

Shared mechanism: CD38 · full Systemic Lupus Erythematosus pipeline

Sanritatug

Developed by Hangzhou Sumgen Biotech Co., Ltd.

Phase 2 in Systemic Lupus Erythematosusmonoclonal antibody
Weak signal

NCT06144710 · Phase 1 · completed

This early-phase study is mainly designed to establish safety and dosing for SG301: the healthy-volunteer portion is open-label and uncontrolled, while the lupus-patient portion is randomized and placebo-controlled but enrolls only a small number of patients per dose group. Clinical disease-activity improvement is a secondary rather than primary measure, and no results have been posted. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment-Emergent Adverse Events(Part A and Part B)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: September 2027 · NCT07447986 (registry estimate)

No aligned efficacy figure on record for this race.

SCTC21C

Developed by Sinocelltech Group Ltd.

Phase 1/2 in Systemic Lupus Erythematosusbiologic (registry-typed, subtype undisclosed)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT07538154 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Systemic Lupus Erythematosus

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSanritatugSCTC21C
SRI-4—Not reported—Not reported
BICLA—Not reported—Not reported
CLASI-50—Not reported—Not reported
Steroid sparing—Not reported—Not reported

SRI-4

Sanritatug
—Not reported
SCTC21C
—Not reported

BICLA

Sanritatug
—Not reported
SCTC21C
—Not reported

CLASI-50

Sanritatug
—Not reported
SCTC21C
—Not reported

Steroid sparing

Sanritatug
—Not reported
SCTC21C
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Sanritatug: no structured comparison results are available for Systemic Lupus Erythematosus.

SCTC21C: no structured comparison results are available for Systemic Lupus Erythematosus.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sanritatug's landscape · SCTC21C's landscape